Kintara Therapeutics Inc
NASDAQ:KTRA

Watchlist Manager
Kintara Therapeutics Inc Logo
Kintara Therapeutics Inc
NASDAQ:KTRA
Watchlist
Price: 6.3 USD -16.43% Market Closed
Market Cap: 266.4m USD
Have any thoughts about
Kintara Therapeutics Inc?
Write Note

Kintara Therapeutics Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kintara Therapeutics Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Kintara Therapeutics Inc
NASDAQ:KTRA
Accounts Payable
$2.2m
CAGR 3-Years
0%
CAGR 5-Years
5%
CAGR 10-Years
25%
Abbvie Inc
NYSE:ABBV
Accounts Payable
$30.5B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accounts Payable
$18.9B
CAGR 3-Years
153%
CAGR 5-Years
80%
CAGR 10-Years
35%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Payable
$4B
CAGR 3-Years
215%
CAGR 5-Years
112%
CAGR 10-Years
59%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Payable
$497.3m
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
27%
No Stocks Found

Kintara Therapeutics Inc
Glance View

Market Cap
266.4m USD
Industry
Biotechnology

Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2016-07-12. The firm is developing two late-stage, Phase III-ready therapeutics. The firm's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The firm is carrying out various clinical trials on brain tumor and solid tumor.

KTRA Intrinsic Value
6.92 USD
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Kintara Therapeutics Inc's Accounts Payable?
Accounts Payable
2.2m USD

Based on the financial report for Jun 30, 2024, Kintara Therapeutics Inc's Accounts Payable amounts to 2.2m USD.

What is Kintara Therapeutics Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
25%

Over the last year, the Accounts Payable growth was -21%.

Back to Top